Zogenix (ZGNX) Tops Q1 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. DOX
4. BKNG
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. FISV

Go back to Zogenix (ZGNX) Tops Q1 EPS by 20c

Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results

May 10, 2016 4:01 PM EDT

EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2016.

Corporate Update

Initiated the first Phase 3 clinical trial of ZX008 in North America for the treatment of seizures in Dravet syndrome, a rare and debilitating form of epilepsy that begins in infancy.  Received Fast Track designation from the FDA for ZX008 in Dravet syndrome. Presented updated data from the... More